Expert: Professor Daniela Krause Director of the Institute of Transfusion Medicine at the University of Mainz  (Germany)

Program:
Overview of significant biological aspects presented during the meeting, including:

00:00 Introduction
01:54 Resistance
11:04 Blast Crisis
13:54 New concepts and new developments
19:37 Q&A Session
20:15 Question 1 - Treating patients resistant to third-line (or more) treatment if BMT is not available
22:24 Question 2 - What is the criteria for ruxolitinib, JAK2 -positive, and or other mutations?
23:58 Question 3 - We see many new TKIs in the pipeline, but where do we stand when talking about finding an actual definitive cure for CML? What is the hottest target for today?
26:45 Question 4 - With the blast crisis study with ponatinib plus azacitidine, did it include transplant eligible patients? And if so, how many were transplanted?
28:24 Question 5 - Daniela, could you outline one particular area of research that you think is the most promising coming forward in regards to clinical need?
29:41 Question 6 - And Jorge, what particularly stood out for you in the biology sessions that you thought would be coming through for clinical use in the near future?
32:05 Thanks

Please click here for the Clinical Highlights

If you have any questions or comments to the speaker, please email info@cml-foundation.org.